Each potential participant satisfied all of the following criteria at screening to be considered eligible for enrolment in the study: 1. Participant must be able to read and provide consent after completing the informed consent process.
-If not heterosexually active at screening, must agree to practice adequate birth control measures if they become heterosexually active during participation in the study (from the start of screening onwards until at least 3 months after the boost vaccination).
-Agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction from the start of screening onwards until at least 3 months after the boost vaccination.
6. Women of non-childbearing potential, defined as postmenopausal (>45 years of age with amenorrhea for ≥2 years or any age with amenorrhea for ≥6 months and serum folliclestimulating hormone [FSH] >40 mIU/mL) or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are not required to use the birth control methods as described in Inclusion Criterion #5. partner is using an adequate method of birth control (see Inclusion Criterion #5), a single-barrier method of birth control for the male participant is acceptable. Men must also agree not to donate sperm from the start of screening onwards until at least 3 months after the boost vaccination.
8. Participant must be available and willing to participate for the duration of the study visits and follow-up.
9. Participant must be willing to provide verifiable identification.
10. Participant must be willing to provide his/her National Insurance/Passport number for the purpose of The Over-volunteering Prevention System (TOPS) registration.
11. Participant must have a means to be contacted.
Exclusion criteria
Any potential participant who met any of the following criteria was excluded from participating in the study:
1. Has been vaccinated with a candidate Ebola vaccine.
Has been diagnosed with Ebola disease or exposed to Ebola including travel to West
Africa in the last 12 months. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone. 8. A woman who is pregnant or breast-feeding, or planning to become pregnant while enrolled in the study or within 3 months after the boost vaccination.
9. Bleeding or clotting disorders.
10. Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would preclude participation (eg, history of seizure disorders, autoimmune disease, any spleen disease, active malignancy, active tuberculosis, asthma, other systemic infections, abnormal laboratory safety parameters*).
* Grade 1 abnormalities for laboratory tests other than those covered in Inclusion
Criterion #4 are not an exclusion criterion. If laboratory tests other than those covered in Inclusion Criterion #4 are out of range (grade 2 or grade 3), repeat of screening tests is permitted once, provided there is an alternative explanation for the out of range value.
11. History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Participants with a history of skin cancer must not be vaccinated at the previous tumor site.
12. Post-organ and/or stem cell transplant whether or not with chronic immunosuppressive therapy.
13. Major surgery (per the investigator's judgment) within the 4 weeks prior to study entry or planned major surgery through the course of the study.
14. History of myocarditis, pericarditis, cardiomyopathy, transient ischemic attack or stroke, myocardial infarction, angina, coronary artery disease, congestive heart failure, clinically significant arrhythmia (including any arrhythmia requiring medication, treatment, or clinical follow-up). Note: urine will be tested to check for current use of amphetamines, benzodiazepines, cocaine, cannabinoids, and opioids.
26. Current alcohol use judged by the investigator to potentially interfere with participant study adherence.
History of chronic urticaria (recurrent hives).
28. Chronic or recurrent use of medications which modify host immune response, eg, cancer chemotherapeutic agents, parenteral corticosteroids. Occurrence of any of the following events after initiation of Cohort 2 in any group in the main study would lead to suspension of further study vaccination in both the main and the substudy, and would trigger a meeting of the DRC to discuss study suspension or discontinuation of further vaccination:
1. One or more participants experience a serious adverse event that is considered to be related to any of the study vaccines; OR 2. One or more participants experience anaphylaxis or generalized urticaria clearly attributable to vaccination with study vaccine; OR 3. Two or more participants experience a severe (grade 3) (non-serious) unsolicited adverse event that is considered to be related to any of the study vaccines; OR 4. Two or more participants experience a severe (grade 3) (non-serious) laboratory abnormality (including unexplained hematuria) considered to be related to any of the study vaccines; OR 5. Two or more participants who received at least one dose of study vaccine to date experience the same severe (grade 3) (non-serious) solicited injection site reaction. (The size [measured in mm] of erythema will not be used as a pausing criterion); OR 6. Two or more participants who received at least one dose of study vaccine to date experience the same severe (grade 3) (non-serious) solicited systemic adverse event considered to be related to any of the study vaccines. (Subjective systemic adverse event corroborated by study personnel.); OR 7. Death of a participant.
Randomizaton
Participants were centrally randomized, using an interactive web response system, to one of four groups (28-day or 56-day interval). Within groups participants were randomly assigned to active vaccine or placebo using randomly permuted blocks. In groups 1 and 3, the block size in the sentinel cohort was 2, with randomization ratio 1:1 (active:placebo), 5 in cohort 1 with randomization ratio 4:1, and 11 in cohort 2 with randomization ratio 10:1. Overall, the randomization ratio was 5:1. In groups 2 and 4, the block size was 6 in both cohort 1 and 2 with randomization ratio 5:1.
ELISA
Optical densities were read at an absorbance wavelength of 450 nm and optical density responses of samples, positive and negative controls were translated into ELISA units/mL using a reference curve consisting of pooled human vaccine responders representing a 1000 ELISA Units/mL. The reference curve was created by an initial dilution of 1:50 followed by a serial dilution of 10 steps, followed by 4PL fitting.
The lower limit of quantification was determined by the analysis of 200 human naïve serum samples at a 1:50 dilution. The optical density results after outlier removal were used to calculate a 95% prediction interval resulting in an optical density value of 0.337. Back calculation of this value on 20 reference curves resulted in a lower limit of quantification of 36.6 ELISA units/mL. Endpoint titers were determined by expressing or extrapolating the highest serum dilution that produced an optical density reading above the cut-off optical density of 0.2.
Ad26 neutralization assay
Ad26-specific neutralizing antibody titers were assessed by luciferase-based virus neutralization assays as described previously and recently optimized and validated for human serum. 1 Serum © 2016 American Medical Association. All rights reserved.
was heat inactivated and serially diluted by 2-fold dilutions (starting dilution 1:16). Ad26.Luc (108 vp/ml) was added to each well at 500 virus particles per cell. A549 cells were added at 104 cells/well and plates were incubated at 37°C/10% CO 2 for 24 hours. After incubation, plates were frozen and subsequently allowed to thaw at room temperature. Luciferase neolite substrate was added and the lysate was transferred into black/white isoplates. Luminescence counts were recorded on a MicroBeta Trilux. Titers were determined by validated software ANAM (adenovirus neutralization assay macro). The limit of detection for the Ad26 neutralizing antibody assay was 16 IC90, the titer at which 90% neutralization was achieved.
T cell assays
Samples were stimulated with peptides covering the glycoprotein from Ebola virus (EBOV), Mayinga variant (Think Peptides, UK). A total of 158 peptides (15 amino acid peptides overlapping by 11 amino acids) were pooled into two pools, EBOV GP1 consisting of 77 and EBOV GP2 of 81 peptides.
An assay control was used in each of the assays stimulated with a CMV pp65 peptide pool with 138 15-mer peptides and overlapping by 11 amino acids. Fisher's exact test was used to define sample positivity based on total count of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and/or IFN-γ producing T cells for CD4+ and CD8+ cells separately. 3 
Thawing of PBMC for ELISpot and intracellular cytokine staining

eAppendix 2: Supplementary results
Serious adverse events
The following serious adverse events were experienced; fractured distal radius (MVA/Ad26-D29 recipient); elective tonsillectomy (MVA/Ad26-D29 recipient); bowel perforation following elective colonoscopy (Ad26/MVA-D57 recipient); severe gastritis (placebo recipient). None were considered related to the study vaccines.
© 2016 American Medical Association. All rights reserved.  solicited adverse events recorded by participant diary for 7 days following each vaccination  all adverse events up to day 21 post boost immunization  serious adverse events were monitored throughout the study. Secondary and exploratory outcomes: Blood samples for humoral assays (secondary outcome), peripheral blood mononuclear cell assays (secondary outcome), and intracellular cytokine staining (exploratory outcome). *follow up of active vaccine recipients only
Randomized Groups
OpenLabel 
